Phase III, Open-Label, Randomized, Multicenter Efficacy and Safety Study of Bendamustine Hydrochloride Versus Chlorambucil in Treatment-Nave Patients with (Binet Stage B/C) B-CLL Requiring Therapy
- Conditions
- B-cell type chronic lymphocytic leukemia (B-CLL)MedDRA version: 6.1Level: PTClassification code 10008958
- Registration Number
- EUCTR2004-000860-28-IT
- Lead Sponsor
- RIBOSEPHARM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method